Our Technology
VACCINE
The Company’s vaccine for COVID19 is based on a ONCoat™ Synthetic Engineered adenovirus vector (Ad5), protected from immune neutralization, and expressing the SARS-CoV-2 spike protein
ONCoat™ Synthetic Vector Vaccine
E1 & E3 deleted replication deficient Ad5 (Human) Adenovirus vector encoding SARS-CoV-2 spike protein
KEY ADVANTAGES
- Protection from adenovirus vector neutralization
- Booster shots are not affected by neutralizing antibodies produced from prior immunizations
- Improved antigen expression
- Encapsulation improves immunity
- Improved vector stability for storage and distribution
KEY ADVANTAGES
ONCoat™ encapsulated SARS-CoV-2 spike protein
- Highest encapsulation capacity reported in literature that improves efficacy
- Easy surface functionalization to increase tissue retention and enhance phagocytic uptake
- Flexible adjustment of nanoparticle size and physical properties to affect the release kinetics
ONCoat™ encapsulated viral RNA
- Effective delivery of viral RNA delivery into cells
- Adjustable slow release over time
- Low cost and easy scalability
- Improved RNA stability
ONCoat™ encapsulated inactivated SARS-CoV-19
- Adjustable slow release over time eliminates the need for booster shots
- Improved efficacy
- Improves the stability of the virus storage and distribution
ONCoat™ encapsulated attenuated SARS-CoV-19
- Most effective to generate immune response but higher chance of clearance and neutralization
- Coating prevents immediate clearance and neutralization and slowly release virus
- Additional phagocyte targeting improves efficacy
- Higher efficacy with lower dose reducing side effects
Designer Encapsulated Vector Assembly